Sicor Inc.

Moran Pirkes

Marco Villa

Alessandro Pontiroli

Nicola Diulgheroff

Jonathan Busolli

Judith Aronhime

Csilla Nemethne Racz

Zvi Harel

Provided are crystalline forms of N-[4-[2-(2-amino-4, 7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]ben-zoyl]-L-glutamic acid, pemetrexed diacid, and processes for the preparation thereof.

Crystalline forms of pemetrexed diacid and processes for the preparation thereof

Provided are crystalline forms of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]ben-zoyl]-L-glutamic acid, pemetrexed diacid, and processes for the preparation thereof.

Provided are crystalline forms of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, pemetrexed diacid, and processes for the preparation thereof.

Provided are processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid, in particular, pemetrexed disodium salt, directly from pemetrexed diacid or salts thereof, i.e., without isolating the obtained pemetrexed salt prior to lyophilizing it.

Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid

Provided are processes for preparing intermediates of pemetrexed.

Processes for preparing intermediates of pemetrexed

The invention provides intermediates of pemetrexed of formula VI and processes for the preparation thereof. 

Growing community of inventors

Turin, Italy

Moran Pirkes